# Manabu Morimoto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/manabu-morimoto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,636 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 43 |
| i10-index | 116 |
| Last Known Institution | Yokohama City University Medical Center |
| OpenAlex ID | https://openalex.org/A5101457577 |
| ORCID iD | 0000-0002-3940-9634 |
| Works | 249 |

## Researcher papers

- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-versus-active-surveillance-in-patients-with/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma](https://scholariq.org/papers/midterm-outcomes-in-patients-with-intermediate-sized-hepatocellular-carcinoma/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)
- [Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial](https://scholariq.org/papers/sorafenib-plus-hepatic-arterial-infusion-chemotherapy-with-cisplatin-versus/)
- [Treatment of hepatocellular carcinoma with radiofrequency ablation: Radiologic-histologic correlation during follow-up periods](https://scholariq.org/papers/treatment-of-hepatocellular-carcinoma-with-radiofrequency-ablation-radiologic/)
- [Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms](https://scholariq.org/papers/antithrombotic-drugs-are-risk-factors-for-delayed-postoperative-bleeding-after/)
- [Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease](https://scholariq.org/papers/feasibility-of-novel-slim-peroral-cholangiopancreatoscopy-for-the-diagnosis-of/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)

## Researcher university

- [Yokohama City University Medical Center](https://scholariq.org/institutions/yokohama-city-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.